Breztri Fundamentals
Clinical Evidence/Outcomes
Appropriate Patient & Use
Safety, Contraindications, and Warnings
Market Landscape & Objections
100

Breztri combines these three classes to treat COPD.

What are an ICS (budesonide), a LAMA (glycopyrrolate), and a LABA (formoterol)?

100

In pivotal trials, Breztri reduced this clinically significant outcome versus dual therapy.

What are moderate/severe COPD exacerbations?

100

Patients with a history of these events despite dual therapy may be candidates for Breztri.

What are frequent or recent COPD exacerbations?

100

Advise this simple step after inhalation to reduce thrush risk.

What is rinse mouth and spit?

100

Many patients are on this bronchodilator combination before stepping up to triple therapy.

What is LABA/LAMA?

200

Breztri is indicated for maintenance treatment of this disease, including reduction of exacerbations.

What is COPD (chronic obstructive pulmonary disease)?

200

Breztri improved this spirometric parameter compared to comparators.

What is FEV1?

200

COPD patients with this inflammatory profile may benefit from ICS-containing regimens.

What is eosinophilic/type 2–associated COPD (higher blood eosinophils)?

200

ICS‑containing COPD regimens carry a risk for this infection; monitor accordingly.

What is pneumonia?

200

The main reason to step up to triple therapy is to reduce these.

What are exacerbations?

300

Adding ICS to LABA/LAMA aims to reduce these events in eosinophil‑associated COPD.

What are exacerbations?

300

Trials showed longer time to first exacerbation with Breztri versus this regimen. 

What is LABA/LAMA dual therapy?

300

Breztri is not indicated for treating this acute condition.

What is acute bronchospasm or acute deteriorations requiring rescue therapy?

300

Use caution in patients with these conditions due to LABA/LAMA effects.

What are coronary disease, arrhythmias, or hypertension?

300

Link value to reductions in this driver of hospitalizations and total cost of care.

What are moderate/severe exacerbations?

400

Compared with dual bronchodilation alone, Breztri offers this incremental benefit for selected patients.

What is reduced exacerbation risk via anti-inflammatory ICS add-on?

400

Patients reported improvements in dyspnea and health status on these questionnaires.

What are tools like TDI and SGRQ (dyspnea and quality-of-life measures)?

400

Counseling should include this foundational lifestyle recommendation for all COPD patients.

What is smoking cessation support?

400

Avoid use in patients with known hypersensitivity to these components.

What are budesonide, glycopyrrolate, formoterol, or excipients?

400

For patients who struggle with high inspiratory flow required by some DPIs, Breztri offers this device advantage.

What is pMDI delivery with Aerosphere co-suspension?

500

Breztri uses this formulation approach to aid delivery across diverse inhalation profiles.

What is Aerosphere pMDI technology (co-suspension for consistent particle delivery)?

500

Exacerbation reduction is more pronounced in patients with this blood marker threshold.

What is elevated blood eosinophils (e.g., ≥100–300 cells/µL, per study analyses)?

500

Consider ICS-containing therapy in patients with overlapping features of this airway disease.

What is asthma–COPD overlap (ACO), per clinician judgment and label consistency?

500

Repeated high ICS exposure may contribute to these systemic risks.

What are adrenal suppression, bone effects, or hyperglycemia (context-dependent)?

500

When clinicians query “who benefits from ICS,” point to this practical lab metric.

What is blood eosinophil count as a guide to ICS responsiveness?

M
e
n
u